Cancel anytime
Alnylam Pharmaceuticals Inc (ALNY)ALNY
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/04/2024: ALNY (1-star) is a SELL. SELL since 1 days. Profits (-1.85%). Updated daily EoD!
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: SELL |
Historic Profit: 12.7% | Upturn Advisory Performance 2 | Avg. Invested days: 32 |
Profits based on simulation | Stock Returns Performance 2 | Last Close 11/04/2024 |
Type: Stock | Today’s Advisory: SELL |
Historic Profit: 12.7% | Avg. Invested days: 32 |
Upturn Star Rating | Stock Returns Performance 2 |
Profits based on simulation Last Close 11/04/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 35.33B USD |
Price to earnings Ratio - | 1Y Target Price 306.7 |
Dividends yield (FY) - | Basic EPS (TTM) -2.63 |
Volume (30-day avg) 769694 | Beta 0.38 |
52 Weeks Range 141.98 - 304.39 | Updated Date 11/4/2024 |
Company Size Large-Cap Stock | Market Capitalization 35.33B USD | Price to earnings Ratio - | 1Y Target Price 306.7 |
Dividends yield (FY) - | Basic EPS (TTM) -2.63 | Volume (30-day avg) 769694 | Beta 0.38 |
52 Weeks Range 141.98 - 304.39 | Updated Date 11/4/2024 |
Earnings Date
Report Date 2024-10-31 | When BeforeMarket |
Estimate -0.93 | Actual -0.87 |
Report Date 2024-10-31 | When BeforeMarket | Estimate -0.93 | Actual -0.87 |
Profitability
Profit Margin -15.86% | Operating Margin (TTM) -15.35% |
Management Effectiveness
Return on Assets (TTM) -2.92% | Return on Equity (TTM) -1500.66% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE - | Forward PE 666.67 |
Enterprise Value 33850755975 | Price to Sales(TTM) 16.87 |
Enterprise Value to Revenue 16.16 | Enterprise Value to EBITDA 204.85 |
Shares Outstanding 128981000 | Shares Floating 128439197 |
Percent Insiders 0.42 | Percent Institutions 95.64 |
Trailing PE - | Forward PE 666.67 | Enterprise Value 33850755975 | Price to Sales(TTM) 16.87 |
Enterprise Value to Revenue 16.16 | Enterprise Value to EBITDA 204.85 | Shares Outstanding 128981000 | Shares Floating 128439197 |
Percent Insiders 0.42 | Percent Institutions 95.64 |
Analyst Ratings
Rating 4.03 | Target Price 229.39 | Buy 11 |
Strong Buy 11 | Hold 8 | Sell 1 |
Strong Sell - |
Rating 4.03 | Target Price 229.39 | Buy 11 | Strong Buy 11 |
Hold 8 | Sell 1 | Strong Sell - |
AI Summarization
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY): A Comprehensive Overview
Company Profile:
Detailed History and Background:
Founded in 2002, Alnylam Pharmaceuticals Inc. (ALNY) is a leading global RNAi therapeutics company. Pioneering the field of RNAi, ALNY focuses on developing innovative treatments for rare genetic and debilitating diseases. The company leverages its proprietary platform to create targeted therapies silencing specific genes, offering hope for patients with unmet medical needs.
Core Business Areas:
- Developing RNAi Therapeutics: ALNY holds the most extensive pipeline of RNAi-based therapies in clinical development, targeting diseases across multiple therapeutic areas, including cardiovascular, metabolic, infectious, and inflammatory disorders.
- Genetic Medicines Platform: Leveraging its proprietary technology, ALNY focuses on silencing disease-causing genes through RNA interference (RNAi), offering a new approach to targeting the root causes of diseases.
Leadership Team and Corporate Structure:
- John Maraganore, Ph.D. (Chairman and Chief Executive Officer): Leading ALNY since its inception, Maraganore is a visionary leader with extensive experience in genomics and drug development.
- R. Kip Boucher, M.D. (Chief Medical Officer): A seasoned physician and leader with more than 20 years of experience in clinical development.
- Ulrich Schmidt, Ph.D. (Chief Scientific Officer): A renowned RNAi expert with over 20 years of experience in gene silencing technology.
- Sheraz Munshi, M.D. (Chief R&D Officer): Bringing over 20 years of experience, Munshi drives research at ALNY.
- Shashi R. Malik (Chief Financial Officer): A finance leader with diverse experience, Malik manages financial strategies.
- Board of Directors: Comprised of experienced individuals from varying backgrounds, including finance, academia, and the pharmaceutical industry.
Top Products and Market Share:
Top Products:
- Onpattro (Patisiran): The first FDA-approved RNAi therapy for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis.
- Givlaari (Givosiran): A treatment for acute hepatic porphyria (AHP), another rare genetic disease.
- Leqvio (Inclisiran): Recently launched in U.S. and EU, Leqvio is the first small interfering RNA (siRNA) approved to lower low-density lipoprotein (LDL) cholesterol.
Market Share:
- Onpattro: Holds significant market share in the hATTR amyloidosis treatment space.
- Givlaari: Market leader in the AHP treatment landscape.
- Leqvio: Expected to capture a substantial portion of the $14 billion LDL-C lowering medication market.
Comparison with Competitors:
ALNY excels with its first-mover advantage in RNAi technology. While competitors exist in specific disease areas, ALNY's broad pipeline and established commercial presence provide a competitive edge.
Total Addressable Market:
The global RNAi therapeutics market is estimated to reach $4 billion by 2026, highlighting the significant opportunity for ALNY's growing portfolio. Additionally, specific markets for approved products like Onpattro and Leqvio offer substantial revenue potential.
Financial Performance:
Recent financials (as of Q1 2023):
- Revenue: $325.7 million (YoY increase of 52%)
- Net Income: $84.5 million
- Profit Margin: 26%
- Earnings per Share (EPS): $0.44
Financial health: Strong revenue growth, positive net income, and rising EPS indicate financial stability and growth potential.
Dividends and Shareholder Returns:
Dividend History: ALNY does not currently pay dividends, as it prioritizes reinvesting profits into research and development.
Shareholder Returns: Over the past year, ALNY stock has risen by approximately 40%, demonstrating strong returns for investors.
Growth Trajectory:
Historical Growth: Revenue has consistently increased over the past 5 years, showcasing a strong growth trajectory.
Future Projections: Analysts expect continued revenue growth fueled by new product launches and market expansion.
Recent initiatives: Strategic collaborations, ongoing clinical trials, and planned product launches position ALNY for continued growth.
Market Dynamics:
Industry Trends: Growing awareness of RNAi technology, increasing investments in gene therapy research, and expanding patient access to specialized treatments are driving industry growth.
Adaptability: ALNY actively engages in partnerships, expands product offerings, and adapts to evolving regulatory landscapes, demonstrating adaptability to market changes.
Competitors:
- Akcea Therapeutics (AKCA): Offering Tegshadi for hATTR amyloidosis treatment.
- Ionis Pharmaceuticals (IONS): Developing multiple RNAi therapies for various indications.
- Moderna (MRNA): mRNA-based therapeutics company, also exploring RNAi technology.
Competitive Advantages: First-mover advantage, diverse pipeline, established commercial presence, and strong R&D capabilities differentiate ALNY from competitors.
Potential Challenges and Opportunities:
Key Challenges:
- Maintaining research and development momentum
- Ensuring market access and affordability for therapies
- Navigating increased competition within the RNAi space.
Potential Opportunities:
- Expanding into new therapeutic areas with its RNAi platform
- Leveraging strategic partnerships and acquisitions for portfolio and market growth
- Capitalizing on the rising demand for personalized medicine solutions.
Recent Acquisitions:
- 2021: Gene Silencing Technology Acquisition from Silence Therapeutics : Granted ALNY exclusive access to novel lipid nanoparticle (LNP) delivery technology, enhancing delivery capabilities for RNAi therapeutics.
- 2020: Prexige Acquisition from Akcea Therapeutics: Added Tegsedi for hATTR amyloidosis to ALNY's portfolio, strengthening its market position in this area.
These acquisitions align with ALNY's strategy to broaden its product portfolio, strengthen technological capabilities, and expand market reach.
AI-Based Fundamental Rating:
Based on an AI analysis considering financial health, market position, and future prospects, ALNY receives a rating of 8.5 out of 10.
This high rating affirms ALNY's strong financial performance, leadership in RNAi technology, and promising growth potential.
Sources and Disclaimers:
Sources:
- Alnylam Pharmaceuticals Inc. website: https://www.alnylam.com/
- SEC filings: https://www.sec.gov/edgar/search
- Market research reports
- News articles
Disclaimer:
This information is for educational purposes only and should not be considered financial advice. Investing involves risk, and you should consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alnylam Pharmaceuticals Inc
Exchange | NASDAQ | Headquaters | Cambridge, MA, United States |
IPO Launch date | 2004-05-28 | CEO & Director | Dr. Yvonne L. Greenstreet M.B.A., MBChB |
Sector | Healthcare | Website | https://www.alnylam.com |
Industry | Biotechnology | Full time employees | 2100 |
Headquaters | Cambridge, MA, United States | ||
CEO & Director | Dr. Yvonne L. Greenstreet M.B.A., MBChB | ||
Website | https://www.alnylam.com | ||
Website | https://www.alnylam.com | ||
Full time employees | 2100 |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.